AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-31. Anything still debated is marked as such rather than presented as settled.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
The major application of uranium in the military sector is in high-density penetrating projectiles. This ammunition consists of depleted uranium (DU) alloyed with 1–2% other elements, such as titanium or molybdenum. At high impact speed, the density, hardness, and pyrophoricity of the projectile enable the destruction of heavily armored targets. Tank armor and other removable vehicle armor can also be hardened with depleted uranium plates. The use of depleted uranium became politically and environmentally contentious after the use of such munitions by the US, UK and other countries during wars in the Persian Gulf and the Balkans raised health questions concerning uranium compounds left in the soil (see Gulf War syndrome). Depleted uranium is also used as a shielding material in some containers used to store and transport radioactive materials. While the metal itself is radioactive, its high density makes it more effective than lead in halting radiation from strong sources such as radium. Other uses of depleted uranium include counterweights for aircraft control surfaces, as ballast for missile re-entry vehicles and as a shielding material. Due to its high density, this material is found in inertial guidance systems and in gyroscopic compasses. Depleted uranium is preferred over similarly dense metals for its ability to be easily machined and cast, as well as its relatively low cost. The main risk of exposure to depleted uranium is chemical poisoning by uranium oxide rather than radioactivity (uranium being only a weak alpha emitter).
== Clinical significance == Levels of the hormone prolactin within the body can indicate various conditions. Normal prolactin levels support reproductive and metabolic functions, while elevated prolactin levels (hyperprolactinemia), and low prolactin levels (hypoprolactinemia) can indicate an underlying medical disorder. Levels of prolactin within the body can also be affected by factors such as pregnancy, stress, and certain medications. Due to the widespread distribution of prolactin receptors across the body’s organs and tissues, elevated levels of prolactin can simultaneously influence multiple organ systems of the body. While prolactin cell levels rise during pregnancy and lactation, they can also rise due to stress, pain, exercise, sexual intercourse, and food consumption. Hyperprolactinemia (elevated prolactin levels) can be caused by excessive thyrotropin-releasing hormone production or decreased dopamine levels. This may cause symptoms in both males and females such as infertility, erectile dysfunction, and irregular periods. Excessive release of prolactin can be due to a prolactinoma, a tumor of the pituitary gland. The tumor itself may not cause symptoms, but may cause an increased production of prolactin and decreased levels of estrogen and testosterone. Symptoms due to a prolactinoma may include infertility, a decrease in sexual desire, and osteoporosis. In men, symptoms may include erectile dysfunction, enlarged breast tissue, and decreased body hair. In women, symptoms may include breast discharge, irregular menstrual cycles, acne, and increased body hair.
Hahn spent February to June 1933 in the United States and Canada as a visiting professor at Cornell University. He gave an interview to the Toronto Star Weekly in which he painted a flattering portrait of Adolf Hitler: I am not a Nazi. But Hitler is the hope, the powerful hope, of German youth... At least 20 million people revere him. He began as a nobody, and you see what he has become in ten years.... In any case for the youth, for the nation of the future, Hitler is a hero, a Führer, a saint... In his daily life he is almost a saint. No alcohol, not even tobacco, no meat, no women. In a word: Hitler is an unequivocal Christ. The April 1933 Law for the Restoration of the Professional Civil Service banned Jews and communists from academia. Meitner was exempt from its impact because she was an Austrian rather than a German citizen. Haber was likewise exempt as a veteran of World War I, but chose to resign his directorship of the Kaiser Wilhelm Institute of Physical Chemistry and Electrochemistry in protest on 30 April 1933. The directors of the other Kaiser Wilhelm Institutes, even the Jewish ones, complied with the new law, which applied to the KWS as a whole and those Kaiser Wilhelm institutes with more than 50% state support, which exempted the KWI for Chemistry. Hahn therefore did not have to fire any of his own full-time staff, but as the interim director of Haber's institute, he dismissed a quarter of its staff, including three department heads. Gerhart Jander was appointed the new director of Haber's old institute, and reoriented it towards chemical warfare research.
They distinguish these systems from other AI because they can pursue goals over many steps, call tools, and carry out tasks with relatively little human intervention. In workshops with regulators, central‑bank officials, and industry specialists, participants highlighted risks both from agentic systems built inside financial institutions and from tools offered by technology firms that can initiate or execute financial actions. In one 2025 forum, 44% of experts surveyed judged autonomous or agentic AI systems to be the most likely current source of AI‑related systemic risk in finance. In March 2025, Scale AI signed a contract with the United States Department of Defense to work with them, in collaboration with Anduril Industries and Microsoft, to develop and deploy AI agents for the purpose of assisting the military with "operational decision-making". In July 2025, Fox Business reported that the company EdgeRunner AI built an offline agent, compressed and fine-tuned on military information, with the CEO seeing more common LLMs as "heavily politicized to the left". As of that time, the company model is being used by the United States Special Operations Command in an overseas deployment. Researchers have expressed concerns that agents and the large language models they are based on could be biased towards aggressive foreign policy decisions. Research-focused agents have the risk of consensus bias and coverage bias due to collecting information available on the public internet.
== History == Zalcitabine was first synthesized in the 1960s by Jerome Horwitz and subsequently developed as an anti-HIV agent by Samuel Broder, Hiroaki Mitsuya, and Robert Yarchoan at the National Cancer Institute (NCI). Like didanosine, it was then licensed because the NCI may not market or sell drugs. The National Institutes of Health (NIH) thus licensed it to Hoffmann-La Roche.
Sources: en.wikipedia.org
Some bacteria, such as Shewanella putrefaciens, Geobacter metallireducens and some strains of Burkholderia fungorum, can use uranium for their growth and convert U(VI) to U(IV). Recent research suggests that this pathway includes reduction of the soluble U(VI) via an intermediate U(V) pentavalent state. Other organisms, such as the lichen Trapelia involuta or microorganisms such as the bacterium Citrobacter, can absorb concentrations of uranium that are up to 300 times the level of their environment. Citrobacter species absorb uranyl ions when given glycerol phosphate (or other similar organic phosphates). After one day, one gram of bacteria can encrust themselves with nine grams of uranyl phosphate crystals; this creates the possibility that these organisms could be used in bioremediation to decontaminate uranium-polluted water. The proteobacterium Geobacter has also been shown to bioremediate uranium in ground water. The mycorrhizal fungus Glomus intraradices increases uranium content in the roots of its symbiotic plant. In nature, uranium(VI) forms highly soluble carbonate complexes at alkaline pH. This leads to an increase in mobility and availability of uranium to groundwater and soil from nuclear wastes which leads to health hazards. However, it is difficult to precipitate uranium as phosphate in the presence of excess carbonate at alkaline pH. A Sphingomonas sp. strain BSAR-1 has been found to express a high activity alkaline phosphatase (PhoK) that has been applied for bioprecipitation of uranium as uranyl phosphate species from alkaline solutions.
=== Microfluidics === Microfluidics, in particular droplet microfluidics, is an emerging tool used to construct new components, and to analyze and characterize them. It is widely employed in screening assays.
Following the initial line (used for a unique description of the sequence) was the actual sequence itself in the standard one-letter character string. Anything other than a valid character would be ignored (including spaces, tabulators, asterisks, etc...). It was also common to end the sequence with an "*" (asterisk) character (in analogy with use in PIR formatted sequences) and, for the same reason, to leave a blank line between the description and the sequence. Below are a few sample sequences:
British garrisons in India contributed 18,534 British officers and men, as well as an estimated 10,000 Indian auxiliaries deployed to assist them. India also sent 7,000 horses, ponies and mules. Indian auxiliaries were only employed in non-combatant roles. The Natal Indian Ambulance Corps, created by Gandhi and financed by the local Indian community, served at the battles of Colenso and Spion Kop.
== Function == BMPs interact with specific receptors on the cell surface, referred to as bone morphogenetic protein receptors (BMPRs). Signal transduction through BMPRs results in mobilization of members of the SMAD family of proteins. The signaling pathways involving BMPs, BMPRs and SMADs are important in the development of the heart, central nervous system, and cartilage, as well as post-natal bone development. They have an important role during embryonic development on the embryonic patterning and early skeletal formation. As such, disruption of BMP signaling can affect the body plan of the developing embryo. For example, BMP4 and its inhibitors noggin and chordin help regulate polarity of the embryo (i.e. back to front patterning). Specifically BMP-4 and its inhibitors play a major role in neurulation and the development of the neural plate. BMP-4 signals ectoderm cells to develop into skin cells, but the secretion of inhibitors by the underlying mesoderm blocks the action of BMP-4 to allow the ectoderm to continue on its normal course of neural cell development. Additionally, secretion of BMPs by the roof plate in the developing spinal cord helps to specify dorsal sensory interneurons. As a member of the transforming growth factor-beta superfamily, BMP signaling regulates a variety of embryonic patterning during fetal and embryonic development. For example, BMP signaling controls the early formation of the Müllerian duct (MD) which is a tubular structure in early embryonic developmental stage and eventually becomes female reproductive tracts.
Sources: en.wikipedia.org
The researchers have set out to answer possible questions from teachers using the program, highlight some minimum recommended training requirements for the software, suggest some "hints and tips" for teaching ideas, explain the importance of performing more studies / trials with the program, overview randomised controlled trial usage of the software, and highlight the importance of obtaining feedback from lesson participants. The recommendations seem to be straightforward and should help in formalising training with the program, as well as in the development of a network of teachers "accredited" to give lessons using the software.
Cammack R, Jackson RH, Cornish-Bowden A, Cole JA (1982). "Electron-spin-resonance studies of the NADH-dependent nitrite reductase from Escherichia coli K12". Biochem. J. 207 (2): 333–9. doi:10.1042/bj2070333. PMC 1153865. PMID 6297458. Lazzarini RA; Atkinson DE (1961). "A triphosphopyridine nucleotide-specific nitrite reductase from Escherichia coli". J. Biol. Chem. 236 (12): 3330–3335. doi:10.1016/S0021-9258(18)94019-6. PMID 14463130. Nicholas DJ, Medina A, Jones OT (1960). "A nitrite reductase from Neurospora crassa". Biochim. Biophys. Acta. 37 (3): 468–76. doi:10.1016/0006-3002(60)90503-5. PMID 14426899. Taniguchi H, Mitsui H, Nakamura K, Egami F. "Ann. Acad. Sci. Fenn. Ser. A II 60 (1955) 200". {{cite journal}}: Cite journal requires |journal= (help) Colandene JD, Garrett RH (1996). "Functional dissection and site-directed mutagenesis of the structural gene for NAD(P)H-nitrite reductase in Neurospora crassa". J. Biol. Chem. 271 (39): 24096–104. doi:10.1074/jbc.271.39.24096. PMID 8798648.
== Other names == As well as being known as 'false enlargement,' when the muscle has been infiltrated by fat tissue, historically it has also been called muscular steatosis, pseudohypertrophic atrophy, lipomatous pseudohypertrophy, interstitial lipomatosis, lipomatous muscular dystrophy, or atrophia lipomatosa. It is also known as fatty atrophy of muscle (not to be confused with fat atrophy, which is atrophy of adipose tissue), as muscle tissue is replaced by fat tissue, the actual muscle atrophies while the fat tissue replaces the bulk.
This resulted in the publication of the report, The Double Bind: The Price of Being a Minority Woman in Science (1976) which made recommendations for recruiting and retaining minority women scientists. Daly was a member of the board of governors of the New York Academy of Sciences for two years. She was a fellow of the American Association for the Advancement of Science and of the American Cancer Society. Daly was designated as a career scientist by the Health Research Council of the City of New York. Daly retired in 1986 from the Albert Einstein College of Medicine, and in 1988 established a scholarship for African American chemistry and physics majors at Queens College in memory of her father. In 1999, she was recognized by the National Technical Association as one of the top 50 women in Science, Engineering and Technology.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.